skip to content

Cambridge Immunology Network



The efficacy of anti-tumour immune responses is reliant on immunogenicity of tumours. Immunogenicity is determined by two main components: antigenicity (presence of neoepitopes that can be presented on MHC class I and recognized by the cytotoxic T cells (CTLs)) and adjuvanticity (presence of signals that will activate antigen presenting cells, such as dendritic cell (DCs), enhancing their capacity to migrate into lymph nodes, license and activate tumour-specific naive T-cells).

We are interested in how tumour-derived signals might regulate functions of dendritic cells, and how cancer cell-dendritic cell interactions can result in immunogenic or tolerogenic responses to tumours. We use co-culture in vitro models to study the communication between cancer cells and dendritic cells, and CRISPR-Cas9 to dissect the pathways governing this communication.

Not available for consultancy


Departments and institutes: